Latest news and press releases about Cytokinetics, Incorporated (CYTK): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Price
| Price | $73.45 |
| Market Cap | $9.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -52.77 |
| EV / EBITDA | -11.34 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 119.00% |
| Return on Invested Capital | -47.74% |
| Return on Assets | -55.10% |
| Gross Margin | 84.97% |
| Operating Margin | -992.98% |
| Net Margin | -1259.87% |
Related companies: ABVX · AXSM · CORT · CRSP · HALO · JAZZ · MRUS
Explore sector: Healthcare · Biotechnology
More sections of CYTK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks